Third-party allogeneic mesenchymal stromal cells prevent rejection in a pre-sensitized high-risk model of corneal transplantation
Lohan, Paul Murphy, Nick Treacy, Oliver Lynch, Kevin Morcos, Maurice Bingling, Chen Ryan, Aideen E. Griffin, Matthew D. Ritter, Thomas
Lohan, Paul
Murphy, Nick
Treacy, Oliver
Lynch, Kevin
Morcos, Maurice
Bingling, Chen
Ryan, Aideen E.
Griffin, Matthew D.
Ritter, Thomas
Loading...
Repository DOI
Publication Date
2018-11-20
Type
Article
Downloads
Citation
Lohan, Paul, Murphy, Nick, Treacy, Oliver, Lynch, Kevin, Morcos, Maurice, Chen, Bingling, Ryan, Aideen E. , Griffin, Matthew D., Ritter, Thomas. (2018). Third-Party Allogeneic Mesenchymal Stromal Cells Prevent Rejection in a Pre-sensitized High-Risk Model of Corneal Transplantation. Frontiers in Immunology, 9(2666). doi: 10.3389/fimmu.2018.02666
Abstract
High-risk cornea transplant recipients represent a patient population with significant un-met medical need for more effective therapies to prevent immunological graft rejection due to heightened anti-donor immune response. In this study, a rat model of pre-existing anti-donor immunity was developed in which comeal allografts were rejected earlier than in non-pre-sensitized recipients. In this model, third-party (non-donor, non-recipient strain) allogeneic mesenchymal stromal cells (allo-MSC) were administered intravenously 7 and 1 days prior to transplantation. Rejection-free graft survival to 30 days post-transplant improved from 0 to 63.6% in MSC-treated compared to vehicle-treated control animals (p =
Publisher
Frontiers Media
Publisher DOI
10.3389/fimmu.2018.02666
Rights
Attribution-NonCommercial-NoDerivs 3.0 Ireland